ALS Drug Study Signals Progress Toward Treatment for Deadly Disease

THE WALL STREET JOURNAL
September 2, 2020
By Jonathan D. Rockoff

“Anything that can slow down the rate of decline in a disease that has no cure—or no treatment to reverse symptoms—is good,” said Jinsy Andrews, who treats ALS patients and directs neuromuscular clinical trials at Columbia University Irving Medical Center. She wasn’t involved in the Amylyx trial. [read more, requires a subscription]